Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

Program highlights for the fiscal year ended March 31, 2025, along with recent developments, include: Patient with advanced/metastatic end-stage pancreatic cancer who responded to MDNA11 treatment ...

Merck’s stock just broke above its 50-day simple moving average, signaling a potential short-term bullish trend despite ...

It boasts more than 80 programs in phase 2 or phase 3 studies. Even with a 25% success rate for these, that should translate ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Jefferies analyst Akash Tewari remains bullish on Merck, maintaining a Buy rating and a $138 price target. The firm’s ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

On 16 March 2024, New Delhi Police arrested Neeraj Chauhan and others for selling fake anti-cancer drugs to patients at a ...

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss. Improving distant ...

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...